EMA Releases Guideline on Covariates in Clinical Trials

Drugmakers planning to assign clinical trial participants to a separate arm of the study based on baseline monitoring must report those plans to the European Medicines Agency, including which factors — called covariates — they plan to rely on to make those assignments.

Often, these covariates are measures taken early in a trial, such as a baseline measurement, that would prompt sponsors to stratify patients into different treatment arms, according to guidance released last week.


RSS Clinical Trials Advisor

  • FDA Finalizes Guidance on Evaluating Drug Effects on Driving Ability December 18, 2017
    The FDA published guidance assisting sponsors in evaluating the effects of psychoactive drugs on the ability to operate a motor vehicle. The agency recommends a tiered approach to evaluating drug effects, consisting of pharmacology/toxicology, epidemiology and clinical behavioral assessments. Data obtained early in development can be used to guide the collection of subsequent data related […]
  • EMA Adopts Guideline on Developing Treatments for Autism December 18, 2017
    The European Medicines Agency adopted a guideline for sponsors developing new products for autism spectrum disorder, providing recommendations on diagnostic criteria, target populations and clinical trial design.
  • EMA Expands Safety Guidance for Developing Anticancer Drugs December 18, 2017
    The European Medicines Agency adopted the fifth revision of its substantive guideline covering all stages of oncology drug development, expanding upon the previous version’s section on safety data.

RSS Good Manufacturing Practices – GMP Newsletter von